CONFIDENTIAL PROTOCOL TITLE: Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence STUDY DRUGS: HERCEPTIN® (Trastuzumab) E75 peptide (KIFGSLAFL, HER2/neu, 369-377) GM-CSF (Leukine®, Berlex) SPONSORS: Genentech, Inc. Galena Biopharma, Inc.